UK doctors adopt new name for PCOS, highlighting broader metabolic risks

After 14 years of discussion, a panel of specialists announced that polycystic ovary syndrome will be officially called polyendocrine metabolic ovarian syndrome (PMOS) in the UK, underscoring its complex hormonal and metabolic nature. The revision moves focus away from ovarian cysts, which many patients do not have, toward brain-ovary signalling and insulin resistance. Patients such as Victoria Hindle, 43, and radio presenter Michelle Akpata recount decades of dismissed symptoms, weight gain and eventual type 2 diabetes before receiving appropriate treatment.

New guidelines advise clinicians to monitor blood-sugar, cholesterol and blood pressure in women with PMOS, not just menstrual issues. Researchers say the name change could improve awareness, though they warn that education for healthcare providers remains essential.